US FDA places clinical hold on Iovance's lung cancer treatment trial

[December 27, 2023]  (Reuters) -The U.S. Food and Drug Administration has placed a clinical hold on Iovance Biotherapeutics' lung cancer therapy trial after a patient death, the company said on Wednesday.

Shares of the company were down 26.9% in premarket trading.

The company said that it will pause enrollment in trial studying LN-145 TIL during the hold, while patients who were previously treated with the therapy for non-small cell lung cancer will continue to be monitored.

The company said that it will work with the FDA to safely resume enrollment as soon as possible.

Non-small cell lung cancer is a disease in which cancer cells form in the tissues of the lung.

The corporate logo of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, 2009. REUTERS/Jason Reed/File Photo

(Reporting by Christy Santhosh; Editing by Shailesh Kuber)

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.